Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer.
From 1 September 1981 to 1 January 1987, 118 patients with FIGO Stage IB, IC, IIA, IIB, and IIC epithelial ovarian cancer were randomized to abdominal irradiation or pelvic irradiation + cyclophosphamide. There was no difference between the regimens with respect to recurrence-free survival (55%) and 4-year overall survival (63%). At routine second-look laparotomy, 16% of patients without clinical detectable tumor showed recurrence. Twenty-five percent of the patients treated with pelvic irradiation + cyclophosphamide had hemorrhagic cystitis, probably caused by radiation damage and cyclophosphamide cystitis. Eight percent had late gastrointestinal symptoms requiring surgery.
Sell
A
A
Department of Oncology, Arhus University Hospital, Denmark.
Bertelsen
K
K
Andersen
J E
JE
Strøyer
I
I
Panduro
J
J
D000005:Abdomen / Q000528:radiation effects*; D000368:Aged; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000473:pathology; D007813:Laparotomy; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D010349:Patient Compliance; D010388:Pelvis / Q000528:radiation effects*; D011832:Radiation Injuries; D011897:Random Allocation; D012086:Reoperation; D016019:Survival Analysis
D003520:Cyclophosphamide